Bay­er tar­gets COPD in a new dis­cov­ery al­liance with Hap­lo­gen, Evotec

Bay­er is adding COPD to its list of dis­cov­ery tar­gets. 

The Ger­man phar­ma com­pa­ny has tied the knot with a col­lab­o­ra­tive ef­fort that’s been un­der­way be­tween Vi­en­na-based Hap­lo­gen and Evotec — a high pro­file dis­cov­ery shop in Eu­rope. They’ll all be work­ing to­geth­er now on new ther­a­peu­tics for pul­monary dis­eases, with a spe­cial fo­cus on COPD.

Re­searchers will be ex­plor­ing for new an­tivi­rals that can pre­vent the repli­ca­tion of a virus in­volved in COPD. And Bay­er will cov­er an undis­closed up­front and oth­er terms to push the al­liance for­ward.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER